Eagle Genomics and Frost & Sullivan Partnership Delivers New Research Paper on Transformative Role of Microbiome Technologies
- Microbiome is crucial modulator of natural world, yet largely untapped
- Partnership delivers insights to commercial R&D teams focused on developing microbiome-focused, sustainable next-generation products and technologies
Cambridge, UK and Santa Clara, California, USA – 1 December 2021 - Today, Eagle Genomics, a pioneer in applying network science to biology, and Frost & Sullivan, the global market analyst and business consulting firm, announced a partnership to deliver insights on the transformative role and potential of microbiome technologies to improve health and wellness knowledge and outcomes. The first outcome of the partnership is a new research report, entitled “Microbiome Technologies Transforming Health & Wellness,” covering a number of case studies on a wide range of microbiome data-driven innovations. The report is being distributed through the Frost & Sullivan ‘TechVision’ series of research and analyses available through the Frost & Sullivan Leadership Council, set up to help organizations succeed in an unpredictable future.
The report highlights a significant increase in the number of patents granted for novel microbiome technologies across academic and industry collaborations, as the microbiome’s status as a crucial modulator of health and wellness in humans, plants and animals becomes more widely appreciated. Such insights are relevant to the biopharma and healthcare industries, as gaining a better understanding of the biodiversity and composition of microbes in both host and environment are fundamental to understanding the microbiome’s link in health and disease.
Frost & Sullivan’s TechVision team analysis identified the exponential growth of ‘Big Data’ as presenting a significant bottleneck in microbiome research. It also discusses how advances in data analytics tools will be invaluable for extracting meaning from microbiome data to unleash the power of microbes across several key applications. The research additionally points to a rising trend in adoption of data analysis platforms, and increasing deployment of software tools designed to simplify complex microbiome data interpretations and to build open microbiome databases to accelerate prediction-based models.
The report also highlights the impact that Eagle Genomics’ AI-augmented knowledge discovery platform e[datascientist]™ has had on companies’ understanding of the link between the microbiome and health and wellness. The platform applies network science to multi-dimensional scientific data, accelerating research and development into complex areas such as the understanding of human-microbiome interactions. In this way, it can support and accelerate innovation workflows including the generation of product claims, as well as promoting reproducibility and traceability of results.
Anthony Finbow, CEO, Eagle Genomics, said: “This analysis demonstrates the fast-growing body of research, literature and technologies around this fascinating and important subject. As our economy focuses ever more on harnessing natural capital, including the microbiome, this reference document serves as a useful guide to organizations trying to understand and exploit the microbiome to improve health and wellness outcomes. It also provides a useful illustration of how Eagle Genomics and our e[datascientist] platform is driving the digital reinvention of science across numerous industries,from AgBio and Food through to Healthcare, Personal Care and Beauty, helping to develop sustainable solutions and tackle the world’s Grand Challenges while unlocking significant economic potential.”
Aarthi Janakiraman, Research Director, Frost & Sullivan TechVision, said: "We are pleased to partner with Eagle Genomics to further the industry’s knowledge of the transformational power of the microbiome, vital work starting with the publication of today’s research report. Eagle Genomics’ e[datascientist] is a holistic microbiome analytics platform that delivers an end-to-end solution including actionable, data-driven insights - enabling and driving disruptive innovation across the entire life sciences R&D value chain. It supports organizations wanting to maximize the potential of ‘Big Data’ in microbiome research, driving waves of innovation across multiple applications and industry segments."